{"id":709375,"date":"2022-11-09T17:34:12","date_gmt":"2022-11-09T22:34:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/"},"modified":"2022-11-09T17:34:12","modified_gmt":"2022-11-09T22:34:12","slug":"xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/","title":{"rendered":"Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BURNABY, British Columbia, Nov.  09, 2022  (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon\u2019s President and Chief Executive Officer, along with Sherry Aulin, Xenon\u2019s Chief Financial Officer, will host fireside chat presentations and participate in one-on-one meetings at the following investor conferences:<\/p>\n<ul>\n<li style=\"text-align:justify\">Guggenheim 4th Annual Immunology and Neurology Day on Monday, November 14, 2022 with a <a href=\"https:\/\/guggenheim.metameetings.net\/events\/neuroimmunology22\/sessions\/43317-xenon-pharmaceuticals-inc\/webcast?gpu_only=true&amp;kiosk=true\" rel=\"nofollow noopener\" target=\"_blank\">fireside chat presentation<\/a> at 10:45\u00a0am\u00a0ET\n<\/li>\n<li style=\"text-align:justify\">Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 with a <a href=\"https:\/\/wsw.com\/webcast\/stifel74\/xene\/2096928\" rel=\"nofollow noopener\" target=\"_blank\">fireside chat presentation<\/a> at 10:20\u00a0am\u00a0ET\n<\/li>\n<li style=\"text-align:justify\">Jefferies London Healthcare Conference on Thursday, November 17, 2022 with a <a href=\"https:\/\/wsw.com\/webcast\/jeff255\/xene\/1854576\" rel=\"nofollow noopener\" target=\"_blank\">fireside chat presentation<\/a> at 10:25\u00a0am\u00a0 GMT (5:25 \u00a0am\u00a0 ET)<\/li>\n<\/ul>\n<p align=\"justify\">Details about company presentations, webcasts, and other events can be found on the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TIZVuMH3Va6xdp44T9SCWv8Pj-OWuuCNYSw1AKWSKQSgp-0sn5X4oJOUUFKtXRbTZJizN_SgrcB41zwl8-2_cyzXVUh9gYUc3ToJSYj-Wc-HvgBh_EU_dT9NtHfriXWQ-QWkF4pxMp_jswZGUjZQ3g==\" rel=\"nofollow noopener\" target=\"_blank\">Investors<\/a>\u201d section of Xenon&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mz0SJRffcYB8RcIZq5QK1EeRQIDRzHz4Ud3Jz5JPEbU0-gJ5u2TRYIlw0--OkDsNYuAdXB7hHtKPnjD6_lfmXDzTs36f1J_qSy_NUA3haq2Pj1o56fJo99acUiZndSQ5\" rel=\"nofollow noopener\" target=\"_blank\">investor.xenon-pharma.com<\/a>. When available, webcasts will be posted for replay following the event. The above-listed dates and times are subject to change.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>About Xenon Pharmaceuticals Inc.<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aiXCrAVRFSETVmJEz_VpjA9N860ZUX1UPs56bZ2ziwEA9-B-YUHRdxp8207wx_Bb4kOAxLJ2GZK3cvY-196qN03jr-7scetRYXMB0C5irqU=\" rel=\"nofollow noopener\" target=\"_blank\">www.xenon-pharma.com<\/a>.<\/p>\n<p align=\"justify\">\u201cXenon\u201d and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.<\/p>\n<p align=\"justify\">\n        <strong>Investor\/Media Contact<\/strong>:<br \/>Jodi Regts<br \/>Xenon Pharmaceuticals Inc.<br \/>Phone: 604.484.3353<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mz0SJRffcYB8RcIZq5QK1MaEpi0ZV24eMcFK1zv6Ybt_symBCDZUCzo56K5ZoeUY9DbEsAFoO2HsB58Z_so6UU-LYQEjtFstxKDu71u_nR0vvky-aQ11SOm7e1SmS9MS\" rel=\"nofollow noopener\" target=\"_blank\">investors@xenon-pharma.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY5MzI0OSM1MjU0NjIxIzIwMTEzODA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MGNhZmRhOGMtZWQ5Ny00ZjdlLTg4OWEtNGFlZWZlOGI0NmYzLTEwMjI5NTM=\/tiny\/Xenon-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BURNABY, British Columbia, Nov. 09, 2022 (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon\u2019s President and Chief Executive Officer, along with Sherry Aulin, Xenon\u2019s Chief Financial Officer, will host fireside chat presentations and participate in one-on-one meetings at the following investor conferences: Guggenheim 4th Annual Immunology and Neurology Day on Monday, November 14, 2022 with a fireside chat presentation at 10:45\u00a0am\u00a0ET Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 with a fireside chat presentation at 10:20\u00a0am\u00a0ET Jefferies London Healthcare Conference on Thursday, November 17, 2022 with a fireside chat presentation at 10:25\u00a0am\u00a0 GMT (5:25 \u00a0am\u00a0 ET) Details about company presentations, webcasts, and other events can be found on the \u201cInvestors\u201d &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-709375","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BURNABY, British Columbia, Nov. 09, 2022 (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon\u2019s President and Chief Executive Officer, along with Sherry Aulin, Xenon\u2019s Chief Financial Officer, will host fireside chat presentations and participate in one-on-one meetings at the following investor conferences: Guggenheim 4th Annual Immunology and Neurology Day on Monday, November 14, 2022 with a fireside chat presentation at 10:45\u00a0am\u00a0ET Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 with a fireside chat presentation at 10:20\u00a0am\u00a0ET Jefferies London Healthcare Conference on Thursday, November 17, 2022 with a fireside chat presentation at 10:25\u00a0am\u00a0 GMT (5:25 \u00a0am\u00a0 ET) Details about company presentations, webcasts, and other events can be found on the \u201cInvestors\u201d &hellip; Continue reading &quot;Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-09T22:34:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY5MzI0OSM1MjU0NjIxIzIwMTEzODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2022-11-09T22:34:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\\\/\"},\"wordCount\":247,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY5MzI0OSM1MjU0NjIxIzIwMTEzODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\\\/\",\"name\":\"Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY5MzI0OSM1MjU0NjIxIzIwMTEzODA=\",\"datePublished\":\"2022-11-09T22:34:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY5MzI0OSM1MjU0NjIxIzIwMTEzODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY5MzI0OSM1MjU0NjIxIzIwMTEzODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/","og_locale":"en_US","og_type":"article","og_title":"Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"BURNABY, British Columbia, Nov. 09, 2022 (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon\u2019s President and Chief Executive Officer, along with Sherry Aulin, Xenon\u2019s Chief Financial Officer, will host fireside chat presentations and participate in one-on-one meetings at the following investor conferences: Guggenheim 4th Annual Immunology and Neurology Day on Monday, November 14, 2022 with a fireside chat presentation at 10:45\u00a0am\u00a0ET Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 with a fireside chat presentation at 10:20\u00a0am\u00a0ET Jefferies London Healthcare Conference on Thursday, November 17, 2022 with a fireside chat presentation at 10:25\u00a0am\u00a0 GMT (5:25 \u00a0am\u00a0 ET) Details about company presentations, webcasts, and other events can be found on the \u201cInvestors\u201d &hellip; Continue reading \"Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/","og_site_name":"Market Newsdesk","article_published_time":"2022-11-09T22:34:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY5MzI0OSM1MjU0NjIxIzIwMTEzODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences","datePublished":"2022-11-09T22:34:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/"},"wordCount":247,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY5MzI0OSM1MjU0NjIxIzIwMTEzODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/","name":"Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY5MzI0OSM1MjU0NjIxIzIwMTEzODA=","datePublished":"2022-11-09T22:34:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY5MzI0OSM1MjU0NjIxIzIwMTEzODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY5MzI0OSM1MjU0NjIxIzIwMTEzODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-pharmaceuticals-to-participate-in-upcoming-investor-conferences-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/709375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=709375"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/709375\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=709375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=709375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=709375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}